We show here that efficacy of immunotherapy against breast tumors can be enhanced by combination therapy with already FDA approved drugs like Tamoxifen and Fulvestrant; known estrogen receptor modulators with very tolerable side effects, thereby extending the potential clinical applications of these drugs. The gene discussed is ESR1; the disease is breast neoplasm.